All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The safety and efficacy of gemtuzumab ozogamicin in infant AML patients
Bookmark this article
On 3rd July 2017, in a Letter to the Editor of Blood, Erin M. Guest from Children’s Mercy Kansas City, Kansas City, and colleagues report results from their study which aimed to determine the safety and efficacy of gemtuzumab ozogamicin (GO), an anti-CD33 humanized antibody, in infants with Acute Myeloid Leukemia (AML) who were treated on two Children Oncology Group (COG) trials, AAML03P1 (NCT00070174) and AAML0531 (NCT00372593).
In this study, the authors combined and analyzed data of infants (less than the age of 1 year) with de novo AML who were randomized to receive standard chemotherapy plus 0.1mg/kg GO in the experimental arm of the AAMLO3P1 study (n = 39 [GO-arm]) and infants in the control arm of the AAML0531 study (n = 103 [No-GO arm]) and standard chemotherapy alone.
The key results of the study were:
- 5-year Overall Survival (OS) in infant AML patients in the GO and No-GO arm from study entry; 66 ± 11% vs 57 ± 12%, P = 0.219
- 5-year Event Free Survival (EFS) in infant AML patients in the GO and No-GO arm from study entry; 47 ± 12% vs 37 ± 12%, P = 0.192
- Early Death (ED [death during induction cycle 1]) rate in infant AML patients in the GO and No-GO arm; 6% vs 5%, P = 0.730
- 5-year Disease Free Survival (DFS) in infant AML patients in the GO and No-GO arm from the end of induction 1; 57 ± 14% vs 42 ± 17%, P = 0.093
- 5-year Relapse Risk (RR) in infant AML patients in the GO and No-GO arm from the end of induction 1; 37 ± 14% vs 55 ± 18%, P = 0.061
- 5-year Treatment Related Mortality (TRM) in infant AML patients in the GO and No-GO arm from the end of induction 1; 2 ± 4% vs 11 ± 23%, P = 0.754
In summation, GO was “well tolerated” and associated with “favorable disease outcomes” in infant patients with de novo AML. The authors suggested that the result of their study “supports a clinical benefit of GO in infants with AML”. They further concluded by stating that “GO can be safely combined with intensive chemotherapy in infants with AML”.
- Guest E.R. et al. Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials, AAML03P1 and AAML0531. Blood. 2017 July 3. DOI: 10.1182/blood-2017-01-762336. [Epub ahead of print].
More about...
Your opinion matters
34 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox